More news about Numab

Intarcia and Numab Reach Key Milestone

15.09.2017 13:44

Related tags

Antibody

Intarcia Therapeutics, Inc., and Numab Therapeutics AG announced the achievement of a key milestone in their on-going development partnership – the selection of a multi-specific antibody construct targeting autoimmune and inflammatory diseases. This delivery triggers a payment to Numab that will bring the total payments for this project to CHF 11.5 million to date. 

This milestone, achieved by utilizing Numab’s innovative discovery and optimization platform to identify a highly potent and selective antibody fragment candidate, also signals an important next step towards realizing the potential of combining Numab’s antibody-based therapeutics with Intarcia’s unique formulation and delivery technology – the Medici Drug Delivery System, a proprietary subcutaneous delivery system that, once placed under the skin, utilizes an osmotic engine that allows drug within the mini-pump to be released in a steady, consistent fashion.

David Urech Ph.D., CSO and co-CEO of Numab, stated “Intarcia’s advanced delivery and formulation technologies set a very high bar for drug developers. We are proud to have successfully generated a robust tri-specific lead candidate for autoimmune disease that has met all predefined biophysical and pharmacological properties in vitro and in non-human primates, and that is ready for the subsequent stage of Intarcia’s formulation development. We are also excited to announce the start of a CHF 30 million financing to accelerate the development of our own proprietary pipeline in cancer and autoimmune disease and move our main program to the clinical research stage.”

“Intarcia is excited to take this next step in our autoimmune and inflammatory disease programs with Numab,” said Kurt Graves, Chairman, President and CEO, Intarcia. “We’re committed to spearheading disruptive innovation by leveraging our proprietary Medici Drug Delivery System. With this new milestone in our partnership, we now have several combination products in our pipeline that we believe can be uniquely optimized for delivery in our Medici system.” 

Picture: Kateryna Kon / Fotolia

(Pres release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

18.01.2019
Editorial

Good times for pioneers

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS